- Conditions
- CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
- Interventions
- Fenfluramine, Placebo
- Drug
- Lead sponsor
- Zogenix, Inc.
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 66
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dravet Syndrome
- Interventions
- No Intervention
- Other
- Lead sponsor
- Encoded Therapeutics
- Industry
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
- Conditions
- CDKL5 Deficiency Disorder (CDD)
- Interventions
- Survey Instrument
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- Not listed
- Enrollment
- 500 participants
- Timeline
- 2018 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Interventions
- Cannabidiol
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more
- Conditions
- Epilepsy, Dravet Syndrome
- Interventions
- GWP42003-P, Placebo Control
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Dravet Syndrome
- Interventions
- STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses
- Drug
- Lead sponsor
- Stoke Therapeutics, Inc
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 18
- States / cities
- San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
- Interventions
- LP352
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- U.S. locations
- 19
- States / cities
- Downey, California • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Dravet Syndrome
- Interventions
- LP352, Placebo
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Dravet Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 50 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Dravet Syndrome (DS), Children Under 2 Years
- Interventions
- fenfluramine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Months to 24 Months
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- LP352
- Drug
- Lead sponsor
- Longboard Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 66 Years
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 16 more
- Conditions
- Dravet Syndrome
- Interventions
- zorevunersen, Sham Comparator
- Drug · Other
- Lead sponsor
- Stoke Therapeutics, Inc
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
- Conditions
- Dravet Syndrome
- Interventions
- Clobazam, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 1 Year to 16 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orlando, Florida • Rochester, Minnesota + 4 more
- Conditions
- Rett Syndrome, MECP2 Duplication, CDKL5, FOXG1 Disorders
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Not listed
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Oakland, California • San Diego, California + 9 more
- Conditions
- Dravet Syndrome (DS)
- Interventions
- Soticlestat, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Lennox-Gastaut Syndrome, Dravet Syndrome
- Interventions
- 12-Lead ECG, Cannabidiol
- Procedure · Drug
- Lead sponsor
- Gillette Children's Specialty Healthcare
- Other
- Eligibility
- 2 Years to 30 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Dravet Syndrome
- Interventions
- Clemizole HCl, Placebo
- Drug
- Lead sponsor
- Epygenix
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 27 more
- Conditions
- Dravet Syndrome
- Interventions
- ETX101
- Drug
- Lead sponsor
- Encoded Therapeutics
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 11
- States / cities
- San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more
- Conditions
- CDKL5 Deficiency Disorder
- Interventions
- ganaxolone, Placebo
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 14 more
- Conditions
- Dravet Syndrome
- Interventions
- ZX008 (Fenfluramine Hydrochloride)
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 35 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- San Francisco, California • Aurora, Colorado
- Conditions
- Dravet Syndrome
- Interventions
- ZX008 (Fenfluramine Hydrochloride), Matching Placebo
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Dravet Syndrome, Seizure Disorder
- Interventions
- ZX008 (Fenfluramine Hydrochloride), Matching Placebo
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 15 more
- Conditions
- Epilepsies, Myoclonic, Drug Resistant Epilepsy
- Interventions
- Lorcaserin
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more
- Conditions
- Rett Syndrome, MECP2 Duplication dIsorder, CDKL5 Disorder, FOXG1 Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Not listed
- Enrollment
- 1,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Oakland, California • San Diego, California + 11 more